Skip to main content
Premium Trial:

Request an Annual Quote

Serologicals Subsidiary to Market Quantum Dot Technology

NEW YORK, March 4 (GenomeWeb News) - Chemicon International, a subsidiary of Serologicals, will market specific quantum dot-containing products from Quantum Dot for the detection of antibody-antigen interactions in immunological experiments, the companies said today.

 

This agreement will "add novel secondary antibody detection technologies to Chemicon's general reagents product portfolio," enabling researchers to study antigen presence in a variety of tissue and cell culture samples, the firms said.

 

Chemicon will sell these products under the Chemicon brand through its direct sales team in North America, Australia, UK, and "much of Europe," as well as through its worldwide network of distributors, the companies said.

Financial terms were not disclosed.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.